Abbott Laboratories Inc. took another step to compete in the transcatheter mitral valve space by exercising its option to buy privately held Cephea Valve Technologies Inc. in full. Financial terms of the deal were not disclosed.
The California-based company is the developer of a minimally invasive heart valve replacement technology. Cephea’s artificial valve is designed to be delivered through a vein in the leg, sparing patients the need for open-heart surgery
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?